Loading clinical trials...

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus

NCT00147745•Daiichi Sankyo

View on ClinicalTrials.gov

Summary

This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients between the ages of 18 - 75, inclusive
•Diagnosed with type 2 diabetes
•Hemoglobin A1c value greater than or equal to 8.0%
•Antidiabetic treatments may include sulfonylurea agents (non-sulfonylurea agents must be withdrawn)
•Overweight, obese (body mass index 25-45 kg/m2)

Exclusion Criteria

•Change of dose of lipid or blood pressure lowering therapy within past three months
•Previous treatment with colesevelam for hyperlipidemia
•Serum triglyceride greater than 500 mg/dL
•Serum low density lipoprotein-cholesterol less than 60 mg/dL

Locations (1)

San Diego VMC

San Diego, California, United States

Key Dates

Start Date

June 1, 2005

Primary Completion Date

January 1, 2008

Completion Date

January 1, 2008

Last Updated

April 2, 2014

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes

Interventions

Colesevelam

DRUG

Colesevelam matching placebo

DRUG

Insulin glargine (Lantus)

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D

Closed-loop in Adults With Type 2 Diabetes